<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638856</url>
  </required_header>
  <id_info>
    <org_study_id>Rjcyto2531</org_study_id>
    <nct_id>NCT03638856</nct_id>
  </id_info>
  <brief_title>Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy</brief_title>
  <official_title>Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Premenopausal Women Underwent to Diagnostic Hysteroscopy: Double-blind, Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research objective To compare effectiveness of oral Misoprostal for cervical priming in
      premenopausal women underwent to diagnostic hysteroscopy Research hypothesis: Null hypothesis
      Effectiveness of oral misoprostal for cervical priming in premenopausal women underwent to
      diagnostic hysteroscopy is not different from placebo Alternative hypothesis: : Oral
      Misoprostal for cervical priming in Premenopausal women underwent to diagnostic hysteroscopy
      is better than placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research design Randomized double-blinded placebo-controlled trial. The investigators who
      assess the outcomes and the participants do not know Misoprostal group or control group. The
      patients are given the random concealed envelop which contains Misoprostal or placebo to take
      before hysteroscopy. Surgeon and the investigator whom assess patients do not know group
      allocation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 30, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>initial cervical diameter</measure>
    <time_frame>1 year</time_frame>
    <description>The initial hedgar dilator number which can easily insert through cervix</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Abnormal Uterine Bleeding</condition>
  <condition>Chronic Pelvic Pain</condition>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Misoprostal group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were added oral Misoprostal 200 mcg 2 tab per oral 3 hour before hysteroscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients were take placebo 2 tab per oral 3 hour before hysteroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 200Mcg Tab</intervention_name>
    <description>patient takes 2 tab of 200 mcg of Misoprostal 3 hr before hysteroscopy</description>
    <arm_group_label>Misoprostal group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Premenopausal women

          2. Patients have following indication for diagnosis hysteroscopy

               -  Abnormal uterine bleeding

               -  Unexplained infertility

               -  Recurrent pregnancy loss

               -  Chronic pelvic pain

               -  Late postpartum hemorrhage

          3. Patients provided written informed consent

        Exclusion Criteria:

          1. Postmenopausal women

          2. Patients who have contraindication for Misoprostal as following

               -  Allergic to Misoprostal

               -  Medical illnesses such as cardiovascular diseases, Asthma, Renal disease

          3. Patients who have contraindication for Hysteroscopoy as following

               -  Pregnant women

               -  Pelvic inflammatory disease

               -  Infection at cervix and vagina

               -  Cervical cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>need to evaluation of cervical priming</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical priming</keyword>
  <keyword>Diagnosis hysteroscopy</keyword>
  <keyword>Oral Misoprostal</keyword>
  <keyword>Premenopause</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

